logo

Biohaven Pharmaceutical Holding Co Ltd. (BHVN)



Trade BHVN now with
  Date
  Headline
5/9/2018 3:03:47 AM Biohaven Initiates Expanded Access Program For Sublingual BHV-0223 ZYDIS Orally Dissolving Tablets For Patients With ALS
4/22/2018 10:02:53 PM Biohaven Announces Robust Clinical Data With Single Dose Rimegepant That Defines Acute And Durable Benefits
4/19/2018 3:03:52 AM Biohaven Pharmaceuticals Announces Additional Phase 3 Rimegepant Data To Be Released At Investor Event Ith 2018 AAN
4/3/2018 3:02:31 AM Kleo Pharmaceuticals Names Luca Rastelli As Chief Scientific Officer
3/26/2018 3:02:26 AM Biohaven Reports Positive Top-line Results From Both Of Its Two Phase 3 Clinical Trials Of Rimegepant
3/12/2018 3:01:47 AM Biohaven Restructures License Deal With Bristol-Myers Squibb To Reduce Royalties Payable On Migraine Product Candidates
3/6/2018 3:01:28 AM Biohaven Enrolls First Patient In Phase 3 Trial To Evaluate Rimegepant Zydis ODT In Acute Treatment Of Migraine
3/1/2018 3:03:58 AM Biohaven Reports Positive Results From Bioequivalence Study With Sublingual Rimegepant Zydis Orally Dissolving Tablet
2/21/2018 3:17:05 AM Biohaven Says License With Catalent For Zydis Orally Dissolving Tablet With Small Molecule CGRP Receptor Antagonists
1/9/2018 3:01:19 AM Biohaven Announces Positive Results From Bioequivalence Study With Sublingual BHV-0223 Zydis Orally Dissolving Tablet
12/21/2017 3:01:51 AM Biohaven Begins Enrollment In Phase 2/3 Clinical Trial Of Trigriluzole In Patients With Obsessive-Compulsive Disorder
11/27/2017 3:01:22 AM Biohaven Completes Enrollment In Study BHV3000-302
11/20/2017 3:03:05 AM Biohaven Receives Agreement From FDA On Initial Pediatric Study Plan For Rimegepant